In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Testagen (KEDG) | Synthetic analog Goserelin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 1 | 583 | |
| Evidence level | Results from lab studies only | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 122 (119 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | None registered | 309 · 71 active108 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Testagen (KEDG) | Goserelin |
|---|---|---|
| Receptor activity and mechanismPharmacology | 11 | 151014 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Zoladex says: “Zoladex 3.6 mg implant: locally confined Stage T2b-T4 prostate carcinoma with flutamide and radiotherapy; palliation of advanced prostate carcinoma; endometriosis; endometrial thinning before ablation for dysfunctional uterine bleeding; palliation of advanced breast cancer in pre- and perimenopausal women”
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Goserelin differs from Gonadorelin at 3 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Testagen (KEDG) found in ClinicalTrials.gov.
Top 3 of 309 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novartis Pharmaceuticals3,246 participants30 Nov 2016 to 9 Nov 2022
Breast Cancer
SWOG Cancer Research Network3,040 participantsMay 1995 to Jun 2013
Prostate Cancer
Radiation Therapy Oncology Group2,028 participantsOct 1994 to 14 May 2018
Prostate Cancer
108 more mention it but do not test it. They only measure it or name it in their text.